IPP Bureau
Aceto acquires specialty exipients company A&C
By IPP Bureau - April 16, 2021
Acquisition of A&C expands Aceto’s Western manufacturing footprint
IMPCL revenue crosses Rs. 160 crore
By IPP Bureau - April 15, 2021
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
Merck publishes sustainability report for 2020
By IPP Bureau - April 13, 2021
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
NATCO receives approval for Ibrutinib tablets from ANDA
By IPP Bureau - April 11, 2021
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Aurore to merge with Solara in an all-stock transaction
By IPP Bureau - April 10, 2021
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Hester to commercialize vaccines for animals
By IPP Bureau - April 09, 2021
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Zydus Cadila announces USFDA approval for Ibrutinib capsules
By IPP Bureau - April 08, 2021
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Dr. Reddy's Laboratories launches Sapropterin Dihydrochloride powder for oral solution in US
By IPP Bureau - April 08, 2021
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Panacea to produce 100 mn doses of Sputnik V vaccine
By IPP Bureau - April 06, 2021
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
GlaxoSmithKline approves sale of Vemgal plant
By IPP Bureau - April 05, 2021
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
By IPP Bureau - April 05, 2021
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
By IPP Bureau - April 05, 2021
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Tatva Chintan Pharma Chem plans for IPO files DRHP with SEBI
By IPP Bureau - April 05, 2021
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
Reports on GSK Pharmaceuticals by ICICI Securities
By IPP Bureau - April 03, 2021
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Lonza completes divestment of two sites to NextPharma
By IPP Bureau - April 02, 2021
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
